29 research outputs found
Summary of patient characteristics.
<p>NA, not applicable.</p><p><sup>a</sup> Shown is the mean ± SEM unless stated otherwise.</p><p><sup>b</sup> Student’s <i>t</i> test with Welch’s Correction for parametric data and 2 × 2 contingency table with Fisher’s Exact Test for categorical data were used.</p><p><sup>c</sup> One PE patient had a twin pregnancy.</p><p><sup>d</sup> Data shown as median.</p><p>Summary of patient characteristics.</p
List of differentially expressed genes in PE decidua (p < 0.001).
<p><sup>a</sup> Weighted to account for effect of the different sample sizes between each transcriptome profiling batch, values above below 0 indicate underexpression in PE relative to control, while values above 0 indicate overexpression in PE relative to control.</p><p><sup>b</sup> Presented as individual p-values from each transcriptome profiling batch.</p><p>List of differentially expressed genes in PE decidua (p < 0.001).</p
Significantly altered pathway categories in PE decidual transcriptome (p < 0.001).
<p><sup>a</sup> Presented as range where appropriate to reflect the spread of individual p-values of each Gene Ontology (GO) set from each transcriptome profiling batch.</p><p>Significantly altered pathway categories in PE decidual transcriptome (p < 0.001).</p
Downstream genes of identified regulators and targets of maternal PE susceptibility genes.
<p>A gene network of downstream targets of identified regulators/targets of maternal PE susceptibility genes was generated with Pathway Studio 9.0. Each link is supported by at least one published reference. Connecting genes are coloured in yellow, regulator/target genes of maternal PE susceptibility genes in red and major downstream targets of these genes in purple.</p
Electrophoretic mobility shift assays for the <i>TNFSF13B</i> SNPs associated with preeclampsia in the Aust/NZ families.
<p>Panel A: Lanes 1 and 6; No nuclear extract, Lanes 2 and 7; nuclear extract only, Lanes 3 and 8, Nuclear extract with unspecific competitor, Lanes 4 and 10; Nuclear extract with specific competitor (unlabelled double stranded oligo for the major allele), Lanes 5 and 9; Nuclear extract with specific competitor (unlabelled double stranded oligo for the minor allele). Panel B: Major shifts without competitor. Lane 1; no nuclear extract, Lane 2; HeLa nuclear extract, Lane 3; T47D nuclear extract. SS; specific shift, US; unspecific shift.</p
Primers used for <i>TNFSF13B</i> PCR amplification and sequencing.
<p>F; Forward primer, R; Reverse primer. For exon 6 an extra set of sequencing primers internal to the PCR amplicon of 430 bp was used.</p
Schematic representation of the <i>TNFSF13B</i> gene and variants detected in a sub-set of founding or proband preeclamptic women from the Aust/NZ study population.
<p>Solid blocks; untranslated exons, open blocks; translated exons.</p
Linkage disequilibrium (LD) pattern for the successfully genotyped <i>TNFSF13B</i> SNPs in the Aust/NZ study population.
<p>LD is measured by the squared value of the pair wise correlation (rho) amongst intra-genic genotypes and the strength of correlation is depicted in the colored bar to the right of the LD plot. The intensity of red color increases with the strength of SNP allele correlation from white (0) indicating no correlation (i.e. no LD) to red (1.0) indicating a perfect correlation (i.e. complete LD).</p
<i>TNFSF13B</i> variants tested in the Aust/NZ and Norwegian study populations.
<p>Novel SNPs are denoted SNP_[UCSC reference template allele][bp position from TSS][alternative allele]. Alleles reported are orientated on the TOP strand (<a href="ftp://ftp.ncbi.nih.gov/snp/database/Illumina_top_bot_strand.note.txt" target="_blank">ftp://ftp.ncbi.nih.gov/snp/database/Illumina_top_bot_strand.note.txt</a>). * ref_assembly, human genome build 36.3, Abbreviations: TSS; translation start site, Chr.; chromosome, Post.; position, bp; base pair, MG<sub>p</sub>; measured genotype test p-value, QTDT<sub>p</sub>; quantitative transmission disequilibrium test p-value, pp; proximal promoter.</p
Oligonucleotides used for Electrophoretic mobility shift assays.
<p>*orientation of oligo: Forward (F)/Reverse (R) strand.</p